Step by Stepa HemeOncBuddy patient portal

Ponatinib

Illustration: Ponatinib

Say it: poh-NA-tih-nib · Brand names: Iclusig

Ponatinib is a strong targeted pill that blocks the abnormal protein that drives some leukemias, even when other pills stop working.

What it is

In some leukemias, an abnormal protein called BCR-ABL tells blood cells to grow out of control. Ponatinib blocks BCR-ABL, including a form called T315I that resists most other pills.

Often used for

How you get it

It is a pill you take by mouth once a day, with or without food. Your team may lower the dose once the leukemia responds. Your schedule may be different.

Common side effects and what helps

Call your care team right away if you have

Before you start, tell your team

Good to know

At home

Questions to ask

Side effect guides

Sources

Quick answers

What is Ponatinib?
Ponatinib is a strong targeted pill that blocks the abnormal protein that drives some leukemias, even when other pills stop working. Brand names: Iclusig.
What is Ponatinib used for?
chronic myeloid leukemia (CML) when other pills did not work or the T315I change is present; acute lymphoblastic leukemia with the Philadelphia chromosome.
How is Ponatinib given?
It is a pill you take by mouth once a day, with or without food. Your team may lower the dose once the leukemia responds. Your schedule may be different.
What are the common side effects of Ponatinib?
High blood pressure. Rash or dry skin. Belly pain. Headache. Joint or muscle pain. Feeling tired. Constipation.
When should I call my care team while taking Ponatinib?
Chest pain, shortness of breath, or pain in your arm, back, neck, or jaw; Numbness or weakness on one side, trouble speaking, or vision loss; Pain, swelling, or redness in one leg or arm; Swelling in your legs, fast weight gain, or trouble breathing when lying down; Yellow skin or eyes, dark urine, or pain on the right side of your belly; Bad headache, or blood pressure higher than your team told you to expect.

Last updated: 2026-10-27. Medically reviewed by Veli Bakalov, MD, medical oncologist (October 2026). General education from Step by Step, the patient portal of HemeOncBuddy.